Do analysts prefer SHPH or SRNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SHPH or SRNE more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Sorrento Therapeutics N/A N/A N/A

Is SRNE or BPTH more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Sorrento Therapeutics N/A N/A N/A Bio-Path N/A -2,842.40% -337.48%

Is CMND or SRNE more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Clearmind Medicine N/A -143.79% -88.51% Sorrento Therapeutics N/A N/A N/A

Do analysts rate VIVS or SRNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate CDT or SRNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CDT or SRNE more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -145.29% -103.25% Sorrento Therapeutics N/A N/A N/A

Sorrento Therapeutics (SRNE) Competitors

$0.0004 0.00 (-60.00%)

As of 07/24/2026 02:37 PM Eastern

Compare

SRNE vs. SHPH, BPTH, CMND, VIVS, and CDT

Should you buy Sorrento Therapeutics stock or one of its competitors? MarketBeat compares Sorrento Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sorrento Therapeutics include Shuttle Pharmaceuticals (SHPH), Bio-Path (BPTH), Clearmind Medicine (CMND), VivoSim Labs (VIVS), and CDT Equity (CDT). These companies are all part of the "pharmaceutical products" industry.

How does Sorrento Therapeutics compare to Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Shuttle Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A
Sorrento Therapeutics	$60.32M	0.00	-$572.84M	-$0.17	N/A

In the previous week, Shuttle Pharmaceuticals had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for Shuttle Pharmaceuticals and 0 mentions for Sorrento Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 0.43 beat Sorrento Therapeutics' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Neutral
Sorrento Therapeutics	Neutral

Shuttle Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sorrento Therapeutics' return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Sorrento Therapeutics	N/A	N/A	N/A

Summary

Shuttle Pharmaceuticals beats Sorrento Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Bio-Path?

Sorrento Therapeutics (NASDAQ:SRNE) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Sorrento Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

Sorrento Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bio-Path has lower revenue, but higher earnings than Sorrento Therapeutics. Bio-Path is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.00	-$572.84M	-$0.17	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

In the previous week, Bio-Path had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
Bio-Path	Neutral

Summary

Sorrento Therapeutics beats Bio-Path on 7 of the 10 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Sorrento Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-143.79%	-88.51%
Sorrento Therapeutics	N/A	N/A	N/A

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Clearmind Medicine has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Clearmind Medicine has higher earnings, but lower revenue than Sorrento Therapeutics. Clearmind Medicine is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A
Sorrento Therapeutics	$60.32M	0.00	-$572.84M	-$0.17	N/A

In the previous week, Clearmind Medicine had 4 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 4 mentions for Clearmind Medicine and 0 mentions for Sorrento Therapeutics. Clearmind Medicine's average media sentiment score of 0.83 beat Sorrento Therapeutics' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Clearmind Medicine	Positive
Sorrento Therapeutics	Neutral

Summary

Sorrento Therapeutics beats Clearmind Medicine on 6 of the 11 factors compared between the two stocks.

How does Sorrento Therapeutics compare to VivoSim Labs?

VivoSim Labs (NASDAQ:VIVS) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, VivoSim Labs had 4 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 4 mentions for VivoSim Labs and 0 mentions for Sorrento Therapeutics. VivoSim Labs' average media sentiment score of 1.12 beat Sorrento Therapeutics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Positive
Sorrento Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

VivoSim Labs has higher earnings, but lower revenue than Sorrento Therapeutics. VivoSim Labs is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$130K	11.25	-$13.84M	-$5.36	N/A
Sorrento Therapeutics	$60.32M	0.00	-$572.84M	-$0.17	N/A

VivoSim Labs has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Sorrento Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Sorrento Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-10,567.17%	-277.62%	-153.77%
Sorrento Therapeutics	N/A	N/A	N/A

Summary

VivoSim Labs and Sorrento Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Sorrento Therapeutics compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, CDT Equity had 4 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Sorrento Therapeutics. CDT Equity's average media sentiment score of 0.47 beat Sorrento Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Neutral
Sorrento Therapeutics	Neutral

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 10.8% of CDT Equity shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CDT Equity has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Sorrento Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-145.29%	-103.25%
Sorrento Therapeutics	N/A	N/A	N/A

CDT Equity has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$1.43 thousand	N/A
Sorrento Therapeutics	$60.32M	0.00	-$572.84M	-$0.17	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CDT Equity beats Sorrento Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRNE vs. The Competition

Export

Metric	Sorrento Therapeutics	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221K	$357.18M	$7.07B	$12.21B
Dividend Yield	N/A	N/A	2.67%	9.80%
P/E Ratio	0.00	N/A	27.14	23.61
Price / Sales	0.00	228.84	523.34	90.24
Price / Cash	N/A	22.44	26.39	46.67
Price / Book	N/A	4.88	10.30	6.08
Net Income	-$572.84M	-$141.03M	$3.60B	$331.70M
7 Day Performance	N/A	-1.69%	-1.27%	-0.63%
1 Month Performance	N/A	-3.98%	-1.67%	-3.04%
1 Year Performance	N/A	41.50%	18.25%	13.30%

Sorrento Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRNE Sorrento Therapeutics	N/A	$0.00 -60.0%	N/A	-71.4%	$221K	$60.32M	N/A	800	High Trading Volume
SHPH Shuttle Pharmaceuticals	1.026 of 5 stars	$3.35 +10.6%	N/A	-92.5%	$1.93M	N/A	N/A	5	Short Interest Increase Gap Down
BPTH Bio-Path	N/A	$0.04 flat	N/A	-72.6%	$1.91M	N/A	N/A	10	News Coverage Gap Up
CMND Clearmind Medicine	1.7725 of 5 stars	$1.64 -12.3%	N/A	-99.6%	$1.91M	N/A	N/A	N/A	Short Interest Decrease Gap Down
VIVS VivoSim Labs	0.9293 of 5 stars	$0.45 -10.9%	N/A	-81.2%	$1.76M	$130K	N/A	20	Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. SHPH, BPTH, CMND, VIVS, and CDT

How does Sorrento Therapeutics compare to Shuttle Pharmaceuticals?

Summary

How does Sorrento Therapeutics compare to Bio-Path?

Summary

How does Sorrento Therapeutics compare to Clearmind Medicine?

Summary

How does Sorrento Therapeutics compare to VivoSim Labs?

Summary

How does Sorrento Therapeutics compare to CDT Equity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. SHPH, BPTH, CMND, VIVS, and CDT

How does Sorrento Therapeutics compare to Shuttle Pharmaceuticals?

Which has better valuation and earnings, SHPH or SRNE?

Does the media favor SHPH or SRNE?

Which has more volatility and risk, SHPH or SRNE?

Do analysts prefer SHPH or SRNE?

Do insiders & institutionals hold more shares of SHPH or SRNE?

Is SHPH or SRNE more profitable?

Summary

How does Sorrento Therapeutics compare to Bio-Path?

Is SRNE or BPTH more profitable?

Which has more volatility and risk, SRNE or BPTH?

Do institutionals and insiders believe in SRNE or BPTH?

Which has higher earnings and valuation, SRNE or BPTH?

Does the media refer more to SRNE or BPTH?

Summary

How does Sorrento Therapeutics compare to Clearmind Medicine?

Is CMND or SRNE more profitable?

Do institutionals and insiders have more ownership in CMND or SRNE?

Which has more volatility & risk, CMND or SRNE?

Which has stronger valuation and earnings, CMND or SRNE?

Does the media favor CMND or SRNE?

Summary

How does Sorrento Therapeutics compare to VivoSim Labs?

Does the media refer more to VIVS or SRNE?

Do analysts rate VIVS or SRNE?

Do insiders & institutionals believe in VIVS or SRNE?

Which has stronger earnings and valuation, VIVS or SRNE?

Which has more volatility and risk, VIVS or SRNE?

Is VIVS or SRNE more profitable?

Summary

How does Sorrento Therapeutics compare to CDT Equity?

Does the media refer more to CDT or SRNE?

Do insiders and institutionals believe in CDT or SRNE?

Which has more volatility & risk, CDT or SRNE?

Is CDT or SRNE more profitable?

Which has better valuation and earnings, CDT or SRNE?

Do analysts rate CDT or SRNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools